- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04155099
Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
Assessment of Cognitive Ability and the Intestinal Microbiome in Individuals With Liver Disease Before and After Investigational Microbiota Restoration Therapeutic
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Julia Garcia-Diaz, MD
- Phone Number: 504-842-7617
- Email: IDResearch@ochsner.org
Study Contact Backup
- Name: Amy Feehan, PhD
- Email: IDResearch@ochsner.org
Study Locations
-
-
Louisiana
-
Jefferson, Louisiana, United States, 70121
- Ochsner Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Individuals who are male or female and are between the ages of 18 and 70 years.
Individuals with a current diagnosis of liver cirrhosis as evidenced by one or more of the following:
a. Liver Biopsy
OR a clinical suspicion of cirrhosis based on the presence of one or more of the following criteria:
- Radiologic evidence of varices, cirrhosis or portal hypertension
- Laboratory evidence of platelet count <100,000 or AST/ALT ratio >1
- Endoscopic evidence of varices or portal gastropathy
- Elastography (i.e. Fibroscan)
- Individuals must have at least one previously documented episode of HE.
- Individuals must be able to read and write in the English language.
- Individuals must be able and willing to utilize the electronic device necessary to measure cognitive function without assistance from outside individuals once the training phase has been completed.
- Individuals must be able to provide valid informed consent prior to any study related procedures.
Exclusion Criteria
- Individuals who are color-blind.
- Individuals actively using psychotropic substances including alcohol.
- Individuals who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. Study individuals are expected to attest to this fact during their participation time. Females who are not surgically sterile or having undergone greater than one year of menopause will receive urine pregnancy tests at screening and initial drug dosing.
- Presence of TIPS (transjugular intrahepatic portosystemic shunt).
- Individuals with an active bacterial infection and are taking antibiotics for those infections at time of consent.
- Individuals with ANC <800 (neutropenia).
- Individuals with MELD >17.
- Individuals with platelet count <35,000/mm3.
Individuals who are immunocompromised due any of the following reasons:
- HIV infection (CD4 count <200/mm3) or AIDS diagnosis
- Inherited/primary immunodeficiency disorders
- Treatment with any anti-neoplastic agent within the last 3 months (excluding locoregional therapy for hepatocellular carcinoma)
- Treatment with any immunosuppressant medications [including but not limited to monoclonal antibodies to B cells or T cells, anti-TNF agents, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine), calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil] within the last 3 months
- Individuals who have previously undergone FMT.
- Individuals with a history of colorectal cancer (all stages).
- Individuals with a history of chronic intrinsic GI diseases such as inflammatory bowel disease (ulcerative colitis, Crohn's disease or microscopic colitis), eosinophilic gastroenteritis, celiac disease or irritable bowel syndrome as determined by Rome III criteria.
- Individuals with a history of colectomy, major gastro-intestinal surgery, or intra-abdominal surgery.
- Individuals with a history of Clostridium difficile infection six months prior to study enrollment.
- Individuals with a history of chronic diarrhea.
- Individuals currently participating in a research trial that involves drug or device intervention.
- Individuals who are unable to fulfill all study criteria.
- Individuals that the PI determines are not capable of participating in the research study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High dose
Capsules of active drug will be supplied in 8-capsule blister packets to be taken twice per week for four weeks.
Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
|
RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules.
The capsules are taken orally (i.e., by mouth).
After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
Other Names:
|
Experimental: Low dose
Capsules of active drug will be supplied in 4-capsule blister packets to be taken twice per week for four weeks.
Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
|
RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules.
The capsules are taken orally (i.e., by mouth).
After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
Other Names:
|
Placebo Comparator: pill quantity-matched Placebo
Capsules of inactive compound will be supplied in 8- or 4-capsule blister packets to be taken twice per week for four weeks.
Blood and stool samples and cognitive assessments will be collected before treatment and at 1, 3, 6, and 12 months after treatment.
|
Capsule with cellulose filler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive function at 1 month post-FMT as measured by change in response times on EncephalApp (Stroop test)
Time Frame: 1 month
|
Determine whether microbiota restoration therapy improves cognition 1 month after treatment by measuring differences in time scores from EncephalApp. The app times participants in seconds (s) in variations of the Stroop Test. The average (s) across all trials will be reported as well as the difference in (s) between (trial 1)-(trial 5). Longer completion times indicate greater cognitive impairment, while a decrease in completion time from trial 1 to trial 5 indicates learning (cognitive improvement). The scale for this measure is theoretically 0s-500s. |
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of HE episodes
Time Frame: 1 month to 12 months
|
Once individuals have one HE episode, they are more likely to experience additional ones, even after complying with standard of care.
The number of HE episodes each study group experiences during the post-treatment follow-up will be compared among treatment groups.
|
1 month to 12 months
|
Engraftment of FMT as assessed by change in type and abundance of gut microbiota following shotgun sequencing
Time Frame: 1 month to 12 months
|
It is anticipated that with treatment, changes in the intestinal microbiota composition of these individuals will likely shift their microbiome to contain different species.
Microbiome analyses will measure, at the family and genus level, which bacteria are present and their relative abundance.
Samples from the same individual at different time points will be compared as well as differences between treatment groups at each time point.
|
1 month to 12 months
|
Change in cognitive function at 3, 6 and 12 months post-FMT as measured by change in response times on EncephalApp (Stroop test)
Time Frame: 3 to 12 months
|
Determine whether microbiota restoration therapy improves cognition 3, 6, and 12 months after treatment by measuring differences in time scores from EncephalApp.
The app times participants in seconds (s) in variations of the Stroop Test.
The average (s) across all trials will be reported as well as the difference in (s) between (trial 1)-(trial 5).
Longer completion times indicate greater cognitive impairment, while a decrease in completion time from trial 1 to trial 5 indicates learning (cognitive improvement).
|
3 to 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlations of clinical variables with primary and secondary outcomes
Time Frame: Duration of the study (0 days to 12 months)
|
Other clinical outcome variables available from individuals' electronic medical records include age, liver-related diagnoses and disease progression, antibiotic usage history, number of previous hospitalizations, and mortality.
This clinical data will be analyzed for significant correlations with the primary and secondary outcome variables.
|
Duration of the study (0 days to 12 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Julia Garcia-Diaz, MD, Ochsner Health System
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019.193
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Consorci Sanitari de l'Alt Penedès i GarrafWithdrawn
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
Clinical Trials on RBX7455
-
Mayo ClinicRebiotix Inc.CompletedClostridium Difficile InfectionUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
McMaster Children's HospitalSt. Justine's HospitalCompletedInflammatory Bowel Diseases | Crohn Disease | Colitis | Pediatric Crohns DiseaseCanada